-
News | 2022.12.07
SpikImm receives a major funding to accelerate the clinical and industrial development of its monoclonal antibodies against SARS-CoV-2
SpikImm, a biotech company founded in 2021 by Truffle Capital in collaboration with the Institut Pasteur, has been awarded a €15 million non-dilutive financing from the French governmentFrance 2030 program for its "PROPHYMAB" project, which is supported as part of the "Emerging Infectious Diseases and CBRN Threats" Acceleration Strategy. SPK001, the first treatment candidate (...
-
Fiche maladie | 2018.12.05
Cystic fibrosis
Cystic fibrosis is the most common severe hereditary genetic disease in the Caucasian population. It is an autosomal recessive inherited disease of the CFTR gene. This fatal condition is characterized by respiratory impairment that affects approximately one in every 2,500 births in Europe and North America. Although the life expectancy of affected individuals has risen considerably since the...
-
News | 2020.10.22
Coronavirus: Institut Pasteur warns against false information circulating on social media
-ENGLISH VERSION COMING SOON-Mis à jour le 20 mars 2023.En 2020-2021, lorsque la pandémie de Covid-19 était à son pic, de nombreuses informations circulaient dans les médias, sur les réseaux sociaux, les messageries instantanées, etc. Ces messages ont pu parfois contenir des informations erronées ou s’appuyant sur des propos attribués à tort à des chercheurs de l’Institut Pasteur à...
-
Document de presse | 2022.10.30
Institut Pasteur Welcomes New, Comprehensive Relationship With UCSF QBI
Two Academic and Scientific Heavyweights Agree to Implement Joint Actions Towards the Creation of a Center of Excellence in Emerging Infectious Diseases with Planned Operations/Locations in Paris and San Francisco. In a ceremony on October 21, 2022, the Institut Pasteur and UC San Francisco Quantitative Biosciences Institute (UCSF QBI) announced a new partnership for the joint establishment...
-
News | 2020.12.01
Use of the maladiecoronavirus.fr web application during the first wave helped reduce call volumes to the French medical emergency number
The maladiecoronavirus.fr web application is a self-triage tool for suspected COVID-19 cases. It was the first application to be approved by the French Ministry of Health in March 2020, and has since been used by almost 13 million people. A study has demonstrated that use of maladiecoronavirus.fr led to an eightfold reduction in the number of unnecessary calls to the French medical emergency...
-
Document de presse | 2020.04.28
Introduction and initial circulation of SARS-CoV-2 in France
Following the emergence of COVID-19 disease in Wuhan in December 2019, syndromic surveillance was implemented in France from January 10, 2020. Two weeks later, the first three imported cases of COVID-19 in Europe were diagnosed in France.The National Reference Center for Respiratory Viruses has been contributing to the genomic surveillance of SARS-CoV-2 for northern France since the first cases...
-
News | 2020.07.03
Existing drugs can prevent SARS-CoV-2 from hijacking cells
Researchers evaluate how the new coronavirus rewires human proteins for its own replication, and identify several antiviral drugs ready for clinical trials.To sum up:An international team of researchers has analysed how SARS-CoV-2, the virus that causes COVID-19, hijacks the proteins in its target cells.The research shows how the virus shifts the cell’s activity to promote its own...
-
Document de presse | 2021.10.26
The intranasal lentiviral vaccine candidate (Lenti-S) protects brain and lung in a pre-clinical animal model
The SARS-CoV-2 virus, responsible for the COVID-19 pandemic, primarily targets the respiratory tract, but its ability to infect cells of the nervous system has also been largely reported. Indeed, the expression of the receptor of this virus, the Angiotensin Converting Enzyme 2 (ACE2), by neuronal and glial cells makes the brain susceptible to SARS-CoV-2. Moreover, neurological manifestations are...
-
Document de presse | 2020.03.20
Editorial: Facing challenges with the novel coronavirus SARS-CoV-2 outbreak
On December 31, 2019, Chinese authorities reported a cluster of pneumonia cases in Wuhan, China, most of which included patients whoreported exposure to a seafood market selling live animals. Emergence of a new pathogenic zoonotic coronavirus (SARS-CoV-2) was suspected. How can we face the challenges with the novel coronavirus SARS-CoV-2 outbreak?Read the editorial of Pr Sylvie van der Werf and...
-
Article | 2020.06.16
Spike glycoprotein, lentiviral vectors and B/T-cell vaccine
Aims: to develop as quickly as possible:an in vitro test to detect and quantify SARS-CoV-2 neutralizing antibodies while avoiding the need to handle the virus. The test will be used to demonstrate the feasibility of vaccine candidates (proof of concept).The availability of a test of this type is crucial in searching for antibodies in samples from patients with Covid-19. These...
